Research programme: immunosuppressive therapeutics - GiulianiAlternative Names: GED 0414
Latest Information Update: 16 Jul 2016
At a glance
- Originator Giuliani
- Developer Nogra Pharma
- Mechanism of Action Immunosuppressants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Immunosuppression
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Immunosuppression in Italy
- 30 Apr 2008 Preclinical trials in Immunosuppression in Italy (unspecified route)